> why this project deserves to succeed
> It doesn't even really support Python, and they should have been more forthcoming about this in the README
From the Codon github page (i.e. their README.md) : "Codon is a Python-compatible language, and many Python programs will work with few if any modifications ... While Codon supports nearly all of Python's syntax, it is not a drop-in replacement ... and a few of Python's dynamic features are disallowed". That seems clear enough - it isn't Python but it is Python-compatible (enough for their purpose).
After the quick README, the next stop is usually the FAQ and, yup, there is "What isn't Codon?" to fill in some background and even point you towards using Codon for the bits it can do and leaving the rest in plain old Python.
> You have to think about the ecosystem
Presumably, you mean all the sorts of tools that will be of interest to the BioInformatics trade? Even from the Seq days: "There are many great bioinformatics libraries on the market today, including Biopython for Python, SeqAn for C++ and BioJulia for Julia. In fact, Seq offers a lot of the same functionality found in these libraries. The advantages of having a domain-specific language and compiler, however, are the higher-level constructs and optimizations..."
Oh, you wanted to apply it elsewhere? Well, if the Python integration does what they indicate, you can make use of all of those libs and bring in Codon piecemeal on the bits that would benefit from the speedup. Just like you already do when linking from Python to a nice fast compiled C library, only without making the full leap to C (or FORTRAN or whatever your analytics are already written in).
> Finally, the restrictive license definitely puts a cap on adoption
As noted above, the licence allows for everything short of use in production (and if you are having to argue about whether your use-case counts as production, e.g. charities, you know you can always talk to the people!). So you can do all your learning and research to see if it *is* useful to you. After that - TALK TO THEM! You *do* know that licences are negotiable, don't you? If you are interesting enough to them, they can cut you a deal!
> the project strikes me as naive when it doesn't address the elephant of the room of why this project deserves to succeed where others have failed
These others (can you name them, just so we're on the same page) - did they have a well-defined market in a growing field, in this case, BioInformatics?